Abstract
Ranibizumab (Lucentis®) is a Fab-Antibody with high affinity for VEGF, and is being designed to bind to all VEGF isoforms. This quality makes it a powerful drug for VEGF inhibition. Diseases of retinal and choroidal blood vessels are the most prevalent causes of moderate and severe vision loss in developed countries. Vascular endothelial growth factor plays a critical role in the pathogenesis of many of these diseases. Results of the pilot studies showed that intraocular injections of ranibizumab (Lucentis®) decrease the mean retinal thickness and improve the BCVA in all the subjects. Proliferative diabetic retinopathy, currently treated with destructive laser photocoagulation, represents another potential target for anti-VEGF therapy. The early experience in animal models with proliferative retinopathy and neovascular glaucoma shows that posterior and anterior neovascularizations are very sensitive to anti-VEGF therapy. The outcome of two phase III clinical trials will increase our knowledge of the role of Lucentis® in the treatment of DME.
Keywords: Ranibizumab, Lucentis, Diabetes, Retinopathy, Macular edema
Current Diabetes Reviews
Title: Ranibizumab for Diabetic Retinopathy
Volume: 5 Issue: 1
Author(s): Monica Rodriguez-Fontal, Virgil Alfaro, John B. Kerrison and Eric P. Jablon
Affiliation:
Keywords: Ranibizumab, Lucentis, Diabetes, Retinopathy, Macular edema
Abstract: Ranibizumab (Lucentis®) is a Fab-Antibody with high affinity for VEGF, and is being designed to bind to all VEGF isoforms. This quality makes it a powerful drug for VEGF inhibition. Diseases of retinal and choroidal blood vessels are the most prevalent causes of moderate and severe vision loss in developed countries. Vascular endothelial growth factor plays a critical role in the pathogenesis of many of these diseases. Results of the pilot studies showed that intraocular injections of ranibizumab (Lucentis®) decrease the mean retinal thickness and improve the BCVA in all the subjects. Proliferative diabetic retinopathy, currently treated with destructive laser photocoagulation, represents another potential target for anti-VEGF therapy. The early experience in animal models with proliferative retinopathy and neovascular glaucoma shows that posterior and anterior neovascularizations are very sensitive to anti-VEGF therapy. The outcome of two phase III clinical trials will increase our knowledge of the role of Lucentis® in the treatment of DME.
Export Options
About this article
Cite this article as:
Rodriguez-Fontal Monica, Alfaro Virgil, Kerrison B. John and Jablon P. Eric, Ranibizumab for Diabetic Retinopathy, Current Diabetes Reviews 2009; 5 (1) . https://dx.doi.org/10.2174/157339909787314239
DOI https://dx.doi.org/10.2174/157339909787314239 |
Print ISSN 1573-3998 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6417 |
Call for Papers in Thematic Issues
Advancing Diabetic Wound Healing: Mechanisms and Interventions
In recent years, diabetic wounds have become a global health concern with the increase in the incidence of diabetes. Diabetic wounds are a kind of chronic and refractory ulcer. It is generally due to the microcirculatory disturbances and the reduced levels of endogenous growth factors. Delayed cutaneous wound healing is ...read more
Oxidative and inflammatory responses in the development of secondary diabetic complications
Diabetes, along with its associated secondary complications, represents a significant global health challenge, contributing significantly to morbidity and mortality. Unhealthy lifestyle habits, reduced physical activity, environmental pollutants, and stress are pivotal factors in the onset of diabetes, particularly type-2 diabetes. Poorly managed hyperglycemia can lead to various complications, including neuropathy, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
In Vivo Optical Imaging in Gene & Cell Therapy
Current Gene Therapy Physiological and Comparative Evidence Fails to Confirm an Adaptive Role for Aging in Evolution
Current Aging Science The Gut Microbiota and the Emergence of Autoimmunity: Relevance to Major Psychiatric Disorders
Current Pharmaceutical Design Prophylactic Vaccine Strategies and the Potential of Therapeutic Vaccines Against Herpes Simplex Virus
Current Pharmaceutical Design Solid Lipid Nanoparticles (SLNs) as a Rising Tool in Drug Delivery Science: One Step Up in Nanotechnology
Current Nanoscience Oxidative stress and myocarditis
Current Pharmaceutical Design CENPA a Genomic Marker for Centromere Activity and Human Diseases
Current Genomics Developments in High-Yield System Expressed Vaccines and Immunotherapy
Recent Patents on Biotechnology Multimodality Imaging of RNA Interference
Current Medicinal Chemistry A Survey on Computational Approaches to the Discovery of microRNA Genes
Current Bioinformatics Advent and Maturation of Regenerative Medicine
Current Stem Cell Research & Therapy Classical and Innovative Insulin Sensitizing Drugs for the Prevention and Treatment of NAFLD
Current Pharmaceutical Design Use of Osmotic Dehydration to Improve Fruits and Vegetables Quality During Processing
Recent Patents on Food, Nutrition & Agriculture Cellular Oxidative/Antioxidant Balance in γ-Irradiated Brain: An Update
Mini-Reviews in Medicinal Chemistry COVID-19 Invades Several Important Organs other than the Lungs: Organs Crosstalk
Coronaviruses MT1-MMP Modulates bFGF-Induced VEGF-A Expression in Corneal Fibroblasts
Protein & Peptide Letters Design, Synthesis and Biological Evaluation of Pyrido[2,3-d] Pyrimidine Derivatives as Potential Anticancer Agents
Letters in Drug Design & Discovery Systemic and Biophase Bioavailability and Pharmacokinetics of Nanoparticulate Drug Delivery Systems
Current Drug Delivery Xanthine Derivatives in the Heart: Blessed or Cursed?
Current Medicinal Chemistry Cross-Talking Between PPAR and WNT Signaling and its Regulation in Mesenchymal Stem Cell Differentiation
Current Stem Cell Research & Therapy